STOCKHOLM, Nov. 19, 2020
STOCKHOLM, Nov. 19, 2020 /PRNewswire/ --
Financial overview July 1 - September 30, 2020
Significant events during the period July 1 - September 30, 2020
Significant events after the reporting period
Jan - Sep
Loss before tax
Loss for the period
Earnings per share before and after dilution (SEK)
Cash flow from operating activities
Cash and cash equivalents at the end of the period
Research & development costs/operating expenses %
Conference call for investors, analysts and the media
The Interim Report Q3 2020 and an operational update will be presented by CEO Marty J Duvall and members of Oncopeptides Leadership team, Thursday November 19, 2020 at 14:00 (CET).
The conference call will also be streamed via a link on the website: www. oncopeptides.com.
Phone numbers for participants from:
Sweden: +46 8 566 426 92
Europe: +44 3333 009 274
USA: +1 833 526 83 47
Year-end Report 2020: February 18, 2021
Annual Report 2020: Week starting with April 26, 2021
Interim Report Q1 2021: May 26, 2021
Annual General Meeting 2021: May 26, 2021
For more information
Marty J Duvall, CEO, Oncopeptides
Rein Piir, Head of Investor Relations, Oncopeptides
Cell phone: +46 70 853 72 92
This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on November 19, 2020.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Based on the results from the HORIZON study a New Drug Application has been submitted to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. The FDA, has granted the New Drug Application a priority review, with a PDUFA date of February 28, 2021.Oncopeptides' global Headquarters is in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
The full report (PDF)
Press release (PDF)